Jacob F. Degner

ORCID: 0000-0003-4898-8575 · 2 papers in corpus

article 2021

Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids

Clinical pharmacokinetics ·doi:10.1007/s40262-021-01096-w

BACKGROUND AND OBJECTIVES: Elagolix is an orally active, gonadotropin-releasing hormone receptor antagonist approved for the management of endometriosis-associated pain and heavy menstrual bleeding associated with uterine fibroids. Elagolix…

article 2018

Population Pharmacokinetics of Elagolix in Healthy Women and Women with Endometriosis

Clinical pharmacokinetics ·doi:10.1007/s40262-018-0629-6

IntroductionElagolix is a novel, orally active, non-peptide, competitive gonadotropin-releasing hormone (GnRH) receptor antagonist in development for the management of endometriosis with associated pain and heavy menstrual bleeding due to u…